With so large a chunk of the economy and medical practice itself inWashington's hands, quality will decline. Ultimately, "our capacity toinnovate and develop new therapies would suffer most of all," asHarvard Medical School Dean Jeffrey Flier recently wrote in our pages.Take the $2 billion annual tax—rising to $3 billion in 2018—that willbe leveled against medical device makers, among the most innovativeU.S. industries. Democrats believe that more advanced healthtechnologies like MRI machines and drug-coated stents are driving coststoo high, though patients and their physicians might disagree.
"The Senate isn't hearing those of us who are closest to the patientand work in the system every day," Brent Eastman, the chairman of theAmerican College of Surgeons, said in a statement for his organizationand 18 other speciality societies opposing ObamaCare.